Male reproductive organ cancer
diseaseOn this page
Also known as cancer of male reproductive organmale genital neoplasmmale reproductive system neoplasmmalignant male reproductive organ neoplasmmalignant Male reproductive system neoplasmmalignant Male reproductive system tumormalignant Male reproductive system tumourmalignant neoplasm of male genital organ, site unspecifiedmalignant neoplasm of male reproductive organmalignant neoplasm of Male reproductive systemmalignant neoplasm of the Male reproductive systemmalignant tumor of male genital organmalignant tumor of Male reproductive systemmalignant tumor of the Male reproductive systemmalignant tumour of male genital organmalignant tumour of Male reproductive systemmalignant tumour of the Male reproductive systemneoplasm of male genital organtumor of male reproductive system
Summary
Male reproductive organ cancer (MONDO:0005836) is a cancer (an umbrella term covering 7 Mondo subtypes) with 22 GWAS associations across 12 studies and 3 clinical trials. Top therapeutic interventions include valproic acid. A subtype of reproductive system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 7 Mondo subtypes
- GWAS associations: 22
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | male reproductive organ cancer |
| Mondo ID | MONDO:0005836 |
| EFO | EFO:0007355 |
| MeSH | D005834 |
| DOID | DOID:3856 |
| NCIT | C8561 |
| SNOMED CT | 363515000 |
| UMLS | C0153606 |
| MedGen | 102279 |
| Anatomy (UBERON) | UBERON:0003135 |
| Is cancer (heuristic) | yes |
Also known as: cancer of male reproductive organ · male genital neoplasm · male reproductive organ cancer · male reproductive system neoplasm · malignant male reproductive organ neoplasm · malignant Male reproductive system neoplasm · malignant Male reproductive system tumor · malignant Male reproductive system tumour · malignant neoplasm of male genital organ, site unspecified · malignant neoplasm of male reproductive organ · malignant neoplasm of Male reproductive system · malignant neoplasm of the Male reproductive system · malignant tumor of male genital organ · malignant tumor of Male reproductive system · malignant tumor of male reproductive system · malignant tumor of the Male reproductive system · malignant tumour of male genital organ · malignant tumour of Male reproductive system · malignant tumour of male reproductive system · malignant tumour of the Male reproductive system (+3 more)
Data availability: 22 GWAS associations (12 studies).
Disease family
This is a subtype of reproductive system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › male reproductive organ cancer
Related subtypes (7): malignant Leydig cell tumor, malignant Sertoli cell tumor, female reproductive organ cancer, prepuce cancer, pituitary cancer, gonadoblastoma, Buschke Lowenstein tumor
Subtypes (7): epididymis cancer, penile cancer, spermatic cord cancer, carcinoma of Cowper glands, testicular cancer, prostate cancer, scrotum cancer
Genetics & variants
GWAS landscape
22 GWAS associations across 12 studies. Top hits map to 17 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs191851063 | 1e-15 | KLF12 | G | 4.07 |
| rs148020284 | 2e-13 | LRATD1 - NBAS | A | 4.73 |
| rs541147603 | 3e-13 | LINC01804 - RNU5E-7P | G | 3.24 |
| rs75467494 | 9e-13 | SAMD3 | G | 3.76 |
| rs543358139 | 2e-12 | LINC01182 - LINC00504 | A | 4.46 |
| rs905839831 | 2e-12 | NWD2 | T | 3.61 |
| rs564906617 | 3e-12 | SOX7-AS1, PINX1, PINX1 | G | 3.56 |
| rs547300358 | 5e-12 | DTWD2 | G | 3.61 |
| rs569391174 | 5e-12 | PCDH15 | A | 2.35 |
| rs373625197 | 8e-12 | XDH | G | 2.66 |
| rs77361099 | 8e-12 | LINC01723 | C | 3.62 |
| rs1452179513 | 1e-11 | PCAT1, CASC8 | C | 2.87 |
| rs148296195 | 1e-11 | TAFA5 | G | 3.03 |
| rs537456754 | 1e-11 | RAD52P1 - ZNF385B | C | 4.01 |
| rs138520938 | 1e-11 | FARS2 | G | 2.35 |
| rs185196738 | 1e-11 | PTPRK - EEF1DP5 | T | 3.32 |
| rs766342104 | 2e-11 | CDC14A | G | 2.33 |
| rs543369884 | 2e-11 | GABRG3 | G | 2.78 |
| rs548212384 | 2e-11 | RN7SKP181 - LINC02253 | T | 5.22 |
| rs143801662 | 2e-11 | SCN4A - PRR29-AS1 | G | 2.33 |
| rs187750301 | 4e-11 | CRISPLD2 | C | 2.28 |
| rs2175058 | 1e-09 | RNU6-1073P - H3P29 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90399477 | Zagkos L | 2024 | 8,988 | 149,131 | Exploring the contribution of lifestyle to the impact of education on the risk of cancer through Mendelian randomization analysis. |
| GCST90477206 | Verma A | 2024 | 2,251 | 412,592 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477207 | Verma A | 2024 | 594 | 415,675 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481512 | Verma A | 2024 | 455 | 416,284 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479805 | Verma A | 2024 | 453 | 103,757 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481511 | Verma A | 2024 | 453 | 103,757 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481510 | Verma A | 2024 | 314 | 53,258 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651317 | Liu TY | 2025 | 219 | 105,312 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90479804 | Verma A | 2024 | 205 | 104,425 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481514 | Verma A | 2024 | 205 | 104,425 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 22 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 21 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 18 |
| intergenic_variant | 4 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs191851063 | 13 | 73799100 | G>A | 0 | intron_variant | KLF12 | 1e-15 | Tier 4: intronic/intergenic |
| rs148020284 | 2 | 14713353 | A>C | 0.001 | intron_variant | LRATD1 - NBAS | 2e-13 | Tier 4: intronic/intergenic |
| rs541147603 | 2 | 15849047 | G>A | 0.001 | intergenic_variant | LINC01804 - RNU5E-7P | 3e-13 | Tier 4: intronic/intergenic |
| rs75467494 | 6 | 130309090 | G>C | 0.001 | intergenic_variant | SAMD3 | 9e-13 | Tier 4: intronic/intergenic |
| rs543358139 | 4 | 14342045 | A>C,T | 0 | intergenic_variant | LINC01182 - LINC00504 | 2e-12 | Tier 4: intronic/intergenic |
| rs905839831 | 4 | 37257929 | T>C | 0 | intron_variant | NWD2 | 2e-12 | Tier 4: intronic/intergenic |
| rs564906617 | 8 | 10765973 | G>A,T | 0 | intron_variant | SOX7-AS1, PINX1, PINX1 | 3e-12 | Tier 4: intronic/intergenic |
| rs547300358 | 5 | 118882153 | G>A | 0 | intron_variant | DTWD2 | 5e-12 | Tier 4: intronic/intergenic |
| rs569391174 | 10 | 55206300 | A>G | 0.001 | intergenic_variant | PCDH15 | 5e-12 | Tier 4: intronic/intergenic |
| rs373625197 | 2 | 31352687 | G>A | 0 | intron_variant | XDH | 8e-12 | Tier 4: intronic/intergenic |
| rs77361099 | 20 | 12970412 | C>T | 0 | intron_variant | LINC01723 | 8e-12 | Tier 4: intronic/intergenic |
| rs1452179513 | 8 | 127291513 | C>G | 0.001 | intron_variant | PCAT1, CASC8 | 1e-11 | Tier 4: intronic/intergenic |
| rs148296195 | 22 | 48657957 | G>A,T | 0 | intron_variant | TAFA5 | 1e-11 | Tier 4: intronic/intergenic |
| rs537456754 | 2 | 179415808 | C>A | 0 | intron_variant | RAD52P1 - ZNF385B | 1e-11 | Tier 4: intronic/intergenic |
| rs138520938 | 6 | 5666366 | G>A | 0.003 | intron_variant | FARS2 | 1e-11 | Tier 4: intronic/intergenic |
| rs185196738 | 6 | 128580049 | T>A,C,G | 0 | intron_variant | PTPRK - EEF1DP5 | 1e-11 | Tier 4: intronic/intergenic |
| rs766342104 | 1 | 100379948 | G>A | 0.001 | intron_variant | CDC14A | 2e-11 | Tier 4: intronic/intergenic |
| rs543369884 | 15 | 27497513 | G>A | 0.001 | intron_variant | GABRG3 | 2e-11 | Tier 4: intronic/intergenic |
| rs548212384 | 15 | 96906564 | T>A,G | 0 | intron_variant | RN7SKP181 - LINC02253 | 2e-11 | Tier 4: intronic/intergenic |
| rs143801662 | 17 | 63987260 | G>A,T | 0.002 | intron_variant | SCN4A - PRR29-AS1 | 2e-11 | Tier 4: intronic/intergenic |
| rs187750301 | 16 | 84834381 | C>T | 0.001 | intron_variant | CRISPLD2 | 4e-11 | Tier 4: intronic/intergenic |
| rs2175058 | 9 | 1005072 | C>A,G,T | 0.05 | intron_variant | RNU6-1073P - H3P29 | 1e-09 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Clonidine | Phase 3 (in late-stage trials) |
| Dexamethasone | Phase 3 (in late-stage trials) |
| Epinephrine | Phase 3 (in late-stage trials) |
| Fospropofol | Phase 3 (in late-stage trials) |
| Propofol | Phase 3 (in late-stage trials) |
| Ropivacaine | Phase 3 (in late-stage trials) |
| St. John’S Wort | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Daratumumab.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01552434 | PHASE1 | TERMINATED | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease |
| NCT03420963 | PHASE1 | TERMINATED | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors |
| NCT02192333 | Not specified | COMPLETED | Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VALPROIC ACID | 4 | 1 |
Related Atlas pages
- Drugs: Valproic Acid